Compare ACADIA Pharmaceuticals Inc. (ACAD) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.86 (market cap $4.49B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $251.92 (market cap $47.86B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 10.7× ACADIA Pharmaceuticals Inc.'s market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | TTWO | |
|---|---|---|
Market Cap | $4.49B | $47.86B |
Sector | Health | Media |
52-Week High | $28.06 | $262.29 |
52-Week Low | $20.06 | $189.69 |
Enterprise Value | $3.69B | $48.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Take-Two Interactive (TTWO) trades at $257.79, up 1.12% with strong bullish momentum driven by Grand Theft Auto VI pre-orders and recent earnings beats. The stock shows technical strength with bullish moving averages, though RSI indicates overbought conditions. Despite negative net income margins, revenue growth to $5.63B in 2025 and analyst consensus of $302.50 price target reflect optimism around the GTA VI launch in November 2026.
Outlook remains positive with GTA VI as a major catalyst, but risks include high debt levels and profitability challenges. Institutional sentiment is strongly bullish with 79% buy ratings, yet investors should monitor execution risks and competitive pressures in the gaming sector. The stock's valuation metrics like P/S of 7.14 suggest growth expectations are priced in.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
